Literature DB >> 10442251

Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.

R de la Fuente-Fernández1.   

Abstract

Dopa-responsive dystonia (DRD) is characterized by striatal dopamine depletion with preserved nigrostriatal terminals. Patients with DRD typically obtain a marked long-term benefit from low doses of levodopa, with no motor complications. By contrast, motor fluctuations and dyskinesias often occur in idiopathic parkinsonism (Parkinson's disease; PD). This suggests that nigrostriatal denervation may be necessary for the development of these levodopa-related motor complications. Six genetically confirmed DRD cases were studied. Three of the five patients who were on chronic levodopa therapy developed choreic dyskinesias, which disappeared on reduction of medication. Apomorphine also induced dyskinesias. In addition, two patients experienced acute dystonic reactions after exposure to dopamine receptor-blocking drugs. No patient showed dose-response motor flutuations during levodopa treatment. It is proposed that striatal dopamine deficiency might play a major role in the pathogenesis of drug-induced dyskinesias. Conversely, the loss of nigrostriatal dopamine terminals seems to be a prerequisite for the development of levodopa-related motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442251

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  5 in total

1.  Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Córdoba (southern Spain).

Authors:  Eduardo López-Laso; Juan José Ochoa-Sepúlveda; Juan José Ochoa-Amor; Enrique Bescansa-Heredero; Rafael Camino-León; Francisco Javier Gascón-Jiménez; Maria Elena Mateos-González; Juan Luis Pérez-Navero; José Ignacio Lao-Villadóniga; Aida Ormazabal; Rafael Artuch; Katrin Beyer
Journal:  J Neurol       Date:  2009-06-16       Impact factor: 4.849

2.  A Severe l-Dopa Responsive Dystonia With Slow and Continuous Improvement in a Patient With a Novel Mutation in the Tyrosine Hydroxylase Gene.

Authors:  Christian Marques Couto; Antônio Pedro Vargas; Fernando Dos Santos Coimbra; Olimar Leite de Assis Cunha; Lucia Willadino Braga
Journal:  Mov Disord Clin Pract       Date:  2019-05-02

Review 3.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

4.  Clinical aspects and management of levodopa-induced dyskinesia.

Authors:  Nicola Tambasco; Simone Simoni; Erica Marsili; Elisa Sacchini; Donatella Murasecco; Gabriela Cardaioli; Aroldo Rossi; Paolo Calabresi
Journal:  Parkinsons Dis       Date:  2012-06-03

Review 5.  Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.

Authors:  Panagiotis Bargiotas; Spyridon Konitsiotis
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-22       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.